SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
February 14, 2000
-----------------------------------------------
Date of Report (Date of earliest event reported)
INHALE THERAPEUTIC SYSTEMS, INC.
---------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 023556 94-3134940
- ------------------------------- ------------- ------------------
(State or other jurisdiction of (Commission (I.R.S. Employer
incorporation) File Number) Identification No.)
150 Industrial Road
San Carlos, CA 94070
--------------------------------------
(Address of principal executive offices)
(650) 631-3100
--------------------------------------------------
(Registrant's telephone number, including area code)
--------------------------------------------------
(Former name, if changed since last report)
1.
ITEM 5. OTHER EVENTS
On February 14, 2000, Inhale Therapeutic Systems, Inc. announced that
the initial purchasers have exercised their $30 million over-allotment option
granted pursuant to a purchase agreement dated February 2, 2000 with respect
to the Company's 5.0% convertible subordinated notes due February 8, 2007.
The closing of the over-allotment increases the aggregate principal amount of
convertible subordinated notes to $230 million. A press release relating to
the issuance is attached hereto as Exhibit 99.1.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS
(c) Exhibits
99.1 Press Release dated February 14, 2000
2.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
INHALE THERAPEUTIC SYSTEMS, INC.
Dated: February 14, 2000 By: /s/ Brigid A. Makes
----------------------------------
Brigid A. Makes
Chief Financial Officer and
Vice President of Finance and
Administration
3.